This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drugdevelopers and physicians – neurologists, neuroradiologists and intensivists.
I enrolled in the Jain Foundation’s natural history study in 2012, and it tracked me for four years, providing data on my disease progression and biomarkers that are essential if companies are going to become interested in drugdevelopment. See if there is a natural history or observational study.
Drugdevelopment The traditional drug discovery process is characterized by its protracted timeline, high costs, and significant attrition rates among drug candidates. There are three main advantages to the use of AI in drugdevelopment: width of research, speed of execution, low costs. 2021 [6] Regina M.
Ever since the first SGLT2 inhibitor (dapagliflozin) was approved by the EU in 2011 and the USA in 2014, it and another nine gliflozin drugsdeveloped since then have been considered for (off-label) use in Type-1 diabetes, as well as in Type-2 diabetes for which they were first approved.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content